Skip to menu Skip to content Skip to footer
Professor Nikolas Haass
Professor

Nikolas Haass

Email: 
Phone: 
+61 7 344 37087

Overview

Background

I am a clinician scientist and academic leader with research in melanoma cell biology and experimental melanoma therapy. I received my degree in medicine from the University of Heidelberg, Germany (1990-1998). I graduated summa cum laude with a PhD in Cell Biology from the University of Heidelberg (1993-1999) and trained in clinical dermatology at the University of Hamburg, Germany (1999-2003). In 2003 I moved to Philadelphia, PA, to work as a post-doctoral fellow in Meenhard Herlyn’s lab at The Wistar Institute (2003-2007). From there I was recruited as an associate faculty member to the Centenary Institute/University of Sydney (2007-2013). In 2013 I commenced a position as Associate Professor for Cutaneous Oncology at University of Queensland Diamantina Institute (now Frazer Institute) and was promoted to full Professor in April 2016.

Availability

Professor Nikolas Haass is:
Available for supervision

Qualifications

  • Doctoral Diploma, Ruprecht Karls Universität Heidelberg

Research impacts

Using cutting-edge technology, including real-time cell cycle imaging in 3D culture and in vivo, my team studies the role of dynamic melanoma heterogeneity in melanomagenesis with the goal to develop novel therapeutic approaches by simultaneously targeting different tumor cell subpopulations. My laboratory and our team are in the unique position to combine sophisticated imaging and biosensor approaches with biochemical methods to provide unprecedented insight to the mechanisms of tumor heterogeneity, tumor-stroma interactions and cancer immunology.

My contribution to the field is best evidenced by 97 original papers and invited reviews in leading biomedical journals. Many of our papers have a large impact in the field (>7500 citations in total, and 19 papers cited >100 times each). The papers in Mol Cancer Ther (2006, cited >500x), Cancer Res (2007, cited 265x) and PNAS (2008, cited 1500x) were evaluated by Faculty 1000 Biology as recommended or exceptional, respectively.

Works

Search Professor Nikolas Haass’s works on UQ eSpace

222 works between 1996 and 2025

161 - 180 of 222 works

2011

Conference Publication

Different ZO-1 Localization in Melanoma, Nevi and their Tumor-Microenvironment - An Indicator of Malignancy

Bohner, C., Haass, N. K., Moll, I, von den Driesch, P., Schaider, H. and Brandner, J. M. (2011). Different ZO-1 Localization in Melanoma, Nevi and their Tumor-Microenvironment - An Indicator of Malignancy. 46. Tagung der Deutschen Dermatologischen Gesellschaft Vereinigung Deutschsprachiger Dermatologen e. V., Dresden, Germany, 30 March - 2 April 2011. Berlin, Germany: Wiley-Blackwell Verlag GmbH. doi: 10.1111/j.1610-0387.2011.07632.x

Different ZO-1 Localization in Melanoma, Nevi and their Tumor-Microenvironment - An Indicator of Malignancy

2011

Journal Article

Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: Pitfalls of the MTS assay

McGowan, Eileen M., Alling, Nikki, Jackson, Elise A., Yagoub, Daniel, Haass, Nikolas K., Allen, John D. and Martinello-Wilks, Rosetta (2011). Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: Pitfalls of the MTS assay. PLoS ONE, 6 (6) e20623, e20623.1-e20623.8. doi: 10.1371/journal.pone.0020623

Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: Pitfalls of the MTS assay

2011

Book Chapter

Cell-cell and cell-matrix contacts in melanoma and the tumor microenvironment

Kuphal, Silke and Haass, Nikolas K. (2011). Cell-cell and cell-matrix contacts in melanoma and the tumor microenvironment. Melanoma Development: Molecular Biology, Genetics and Clinical Application. (pp. 181-215) edited by Anja Bosserhoff. Vienna, Austria: SpringerWienNewYork. doi: 10.1007/978-3-7091-0371-5

Cell-cell and cell-matrix contacts in melanoma and the tumor microenvironment

2011

Book Chapter

Egretta schistacea: Kuestenreiher

Haass, N. K. and Bauer, H.-G. (2011). Egretta schistacea: Kuestenreiher. Nicht-Singvögel: Rheidae (Nandus) - Phoenicopteridae (Flamingos). (pp. 266-268) edited by Jochen Hölzinger and Hans-Günther Bauer. Stuttgart, Germany: Ulmer Eugen Verlag.

Egretta schistacea: Kuestenreiher

2010

Conference Publication

Tropomyosin Tm5NM1: A novel target for cancer therapy

Stehn, J., Schevzov, G., Bonello, T., McCluskey, A., Haass, N., Palmer, S., Hardeman, E., Allanson, M., Reeve, V. and Gunning, P. (2010). Tropomyosin Tm5NM1: A novel target for cancer therapy. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin Germany, Nov 16-19, 2010. PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/S1359-6349(10)72041-3

Tropomyosin Tm5NM1: A novel target for cancer therapy

2010

Conference Publication

Tight Junction - specific proteins are absent from melanoma while ZO-1 is widely expressed

Bohner, C., Vidal-y-Sy, S., Moll, I, von den Driesch, P., Haass, N. K., Schaider, H. and Brandner, J. M. (2010). Tight Junction - specific proteins are absent from melanoma while ZO-1 is widely expressed. WILEY-BLACKWELL.

Tight Junction - specific proteins are absent from melanoma while ZO-1 is widely expressed

2010

Journal Article

Genetics of basal cell carcinoma

De Zwaan, Sally E. and Haass, Nikolas K. (2010). Genetics of basal cell carcinoma. Australasian Journal of Dermatology, 51 (2), 81-92. doi: 10.1111/j.1440-0960.2009.00579.x

Genetics of basal cell carcinoma

2010

Conference Publication

Modification of the sphingosine kinase pathway as a novel therapeutic approach for melanoma

Douglas, G., Kaczorowski, D., McGowan, E., Anfosso, A., Xia, P., Weninger, W. and Haass, N. K. (2010). Modification of the sphingosine kinase pathway as a novel therapeutic approach for melanoma. 37th Annual Meeting of the Arbeitsgemeinschaft-Dermatologishche-Forschung, Luebeck Germany, Feb 18-20, 2010. ELSEVIER GMBH, URBAN & FISCHER VERLAG.

Modification of the sphingosine kinase pathway as a novel therapeutic approach for melanoma

2010

Journal Article

Multiple desmoplastic melanomas in Birt-Hogg-Dubé syndrome and a proposed signaling link between folliculin, the mTOR pathway, and melanoma susceptibility

Cocciolone, Raymond A., Crotty, Kerry A., Andrews, Lesley, Haass, Nikolas K. and Moloney, Fergal J. (2010). Multiple desmoplastic melanomas in Birt-Hogg-Dubé syndrome and a proposed signaling link between folliculin, the mTOR pathway, and melanoma susceptibility. Archives of Dermatology, 146 (11), 1316-1318. doi: 10.1001/archdermatol.2010.333

Multiple desmoplastic melanomas in Birt-Hogg-Dubé syndrome and a proposed signaling link between folliculin, the mTOR pathway, and melanoma susceptibility

2010

Journal Article

Melanoma progression exhibits a significant impact on connexin expression patterns in the epidermal tumor microenvironment

Haass, Nikolas K., Ripperger, D., Wladykowski, E., Dawson, P., Gimotty, P. A., Blome, C., Fischer, F., Schmage, P., Moll, I. and Brandner, Johanna M. (2010). Melanoma progression exhibits a significant impact on connexin expression patterns in the epidermal tumor microenvironment. Histochemistry and Cell Biology, 133 (1), 113-124. doi: 10.1007/s00418-009-0654-5

Melanoma progression exhibits a significant impact on connexin expression patterns in the epidermal tumor microenvironment

2010

Journal Article

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

Lee, John T., Li, Ling, Brafford, Patricia A., Van Den Eijnden, Marcia, Halloran, Molly B., Sproesser, Katrin, Haass, Nikolas K., Smalley, Keiran S. M., Tsai, James, Bollag, Gideon and Herlyn, Meenhard (2010). PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell and Melanoma Research, 23 (6), 820-827. doi: 10.1111/j.1755-148X.2010.00763.x

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

2009

Conference Publication

Inhibition of MEK with AZD6244 is cytostatic as a monotherapy in melanoma, but cytotoxic when combined with docetaxel leading to tumour regression in vitro and in vivo

Haass, Nikolas K., Sproesser, Katrin, Nguyen, Thiennga K., Contractor, Rooha, Herlyn, Meenhard and Smalley, Keiran S. M. (2009). Inhibition of MEK with AZD6244 is cytostatic as a monotherapy in melanoma, but cytotoxic when combined with docetaxel leading to tumour regression in vitro and in vivo. 5th Annual Scientific Meeting of the Australasian-Society-for-Dermatology-Research, Sydney Australia, May 21-22, 2008. NATURE PUBLISHING GROUP.

Inhibition of MEK with AZD6244 is cytostatic as a monotherapy in melanoma, but cytotoxic when combined with docetaxel leading to tumour regression in vitro and in vivo

2009

Conference Publication

Connexin expression patterns in the epidermal tumour microenvironment of melanoma are valuable biomarkers for diagnosis and prognosis

Haass, N. K., Ripperger, D., Wladykowski, E., Dawson, P., Gimotty, P. A., Reich, C., Fischer, F., Schmage, P., Moll, I. and Brandner, J. M. (2009). Connexin expression patterns in the epidermal tumour microenvironment of melanoma are valuable biomarkers for diagnosis and prognosis. 5th Annual Scientific Meeting of the Australasian-Society-for-Dermatology-Research, Sydney Australia, May 21-22, 2008. NATURE PUBLISHING GROUP.

Connexin expression patterns in the epidermal tumour microenvironment of melanoma are valuable biomarkers for diagnosis and prognosis

2009

Conference Publication

NOXA inhibits melanoma growth and invasion in 3D models

Mohana-Kumaran, N., Lucas, K. M., Weninger, W., Allen, J. D. and Haass, N. K. (2009). NOXA inhibits melanoma growth and invasion in 3D models. 5th Annual Scientific Meeting of the Australasian-Society-for-Dermatology-Research, Sydney Australia, May 21-22, 2008. NATURE PUBLISHING GROUP.

NOXA inhibits melanoma growth and invasion in 3D models

2009

Conference Publication

Tight junction proteine in merkel cell carcinoma

Fuchs, F., Moll, I, Haass, N. K., Houdek, P., Wladykowski, E. and Brandner, J. M. (2009). Tight junction proteine in merkel cell carcinoma. MALDEN: WILEY-BLACKWELL PUBLISHING, INC.

Tight junction proteine in merkel cell carcinoma

2009

Conference Publication

Novel small molecule kinase inhibitors with potent and specific anti-melanoma activity

Haass, N. K., Smalley, K. S., Lee, J. T., Weninger, W. and Herlyn, M. (2009). Novel small molecule kinase inhibitors with potent and specific anti-melanoma activity. 69th Annual Meeting of the Society-of-Investigative-Dermatology, Montreal Canada, May 06-09, 2009. NATURE PUBLISHING GROUP.

Novel small molecule kinase inhibitors with potent and specific anti-melanoma activity

2009

Conference Publication

ZO-1 in malignant melanoma and adjacent epidermis

Bohner, C., Haass, N. K., Ripperger, D., Wladykowski, E., Moll, I. and Brandner, J. (2009). ZO-1 in malignant melanoma and adjacent epidermis. 36th Annual Meeting of the Arbeitsgemeinschaft-Dermatologishche-Forschung, Heidelberg Germany, Mar 05-07, 2009. WILEY-BLACKWELL.

ZO-1 in malignant melanoma and adjacent epidermis

2009

Conference Publication

Targeted therapy of melanoma: Novel kinase inhibitors with potent and specific anti-melanoma activity

Haass, N. K., Smalley, K. S., Lee, J. T. and Herlyn, M. (2009). Targeted therapy of melanoma: Novel kinase inhibitors with potent and specific anti-melanoma activity. 36th Annual Meeting of the Arbeitsgemeinschaft-Dermatologishche-Forschung, Heidelberg Germany, Mar 05-07, 2009. WILEY-BLACKWELL.

Targeted therapy of melanoma: Novel kinase inhibitors with potent and specific anti-melanoma activity

2009

Conference Publication

Usability of Connexin 26, 30 and 43 as markers for diagnosis and prognosis of malignant melanoma

Haass, N. K., Ripperger, D., Wladykowski, E., Fischer, F., Schmage, P., Moll, I. and Brandner, J. M. (2009). Usability of Connexin 26, 30 and 43 as markers for diagnosis and prognosis of malignant melanoma. 36th Annual Meeting of the Arbeitsgemeinschaft-Dermatologishche-Forschung, Heidelberg Germany, Mar 05-07, 2009. WILEY-BLACKWELL.

Usability of Connexin 26, 30 and 43 as markers for diagnosis and prognosis of malignant melanoma

2009

Journal Article

Melanoma Biomarkers Current Status and Utility in Diagnosis, Prognosis, and Response to Therapy

Haass, Nikolas K. and Smalley, Keiran S. M. (2009). Melanoma Biomarkers Current Status and Utility in Diagnosis, Prognosis, and Response to Therapy. Molecular Diagnosis and Therapy, 13 (5), 283-296. doi: 10.1007/BF03256334

Melanoma Biomarkers Current Status and Utility in Diagnosis, Prognosis, and Response to Therapy

Funding

Past funding

  • 2023 - 2024
    Changing the melanoma tumour microenvironment to improve both targeted and immune therapy
    Australasian College of Dermatologists Scientific Research Fund
    Open grant
  • 2022 - 2023
    Laser capture microdissection to empower cancer discoveries, improve diagnosis, treatment and outcomes in amyloidosis patients
    IPF Healthy - Medical Research
    Open grant
  • 2020 - 2023
    Mathematical models of 4D multicellular spheroids (ARC Discovery Project administered by Queensland University of Technology)
    Queensland University of Technology
    Open grant
  • 2019
    Improving Immune Checkpoint Therapy of Melanoma
    Australasian College of Dermatologists Scientific Research Fund
    Open grant
  • 2019 - 2022
    Induction of endoplasmic reticulum stress to potentiate immunogenic cell death to improve melanoma therapy
    Cancer Council Queensland
    Open grant
  • 2018 - 2022
    Improving outcomes for patients with melanoma brain metastases using novel personalised and response-adapted treatment strategies (PARF Translation Research Innovation Award administered by MSHHS)
    Metro South Hospital and Health Service
    Open grant
  • 2017 - 2024
    ACRF Cancer Ultrastructure and Function Facility
    Australian Cancer Research Foundation
    Open grant
  • 2017 - 2019
    Melanoma environment and heterogeneity in therapy sensitivity and resistance - Haass
    Meehan Bequest
    Open grant
  • 2017 - 2018
    Personalized medicine for renal cell carcinoma patients: use of patient-derived tumors for 3-D cell culture and animal models
    UQ-Ochsner Seed Fund for Collaborative Research - MABS funds
    Open grant
  • 2016
    Epigenetic remodelling driving acquired permanent drug resistance in melanoma cells
    PA Research Foundation
    Open grant
  • 2015 - 2018
    Defining the role of Microphthalmia-associated Transcription Factor (MITF) in melanoma heterogeneity by real-time cell cycle imaging
    NHMRC Project Grant
    Open grant
  • 2015
    Next-generation cell analysis: Automated high-throughput 3D microscope and multimode microplate reader
    NHMRC Equipment Grant
    Open grant
  • 2014
    Purchase of low O2 incubator and Dissociator
    NHMRC Equipment Grant
    Open grant
  • 2013 - 2014
    Real-time Imaging of cell cycle progression in melanoma
    NHMRC Project Grant
    Open grant

Supervision

Availability

Professor Nikolas Haass is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

For media enquiries about Professor Nikolas Haass's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au